(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 6.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Jazz Pharmaceuticals's revenue in 2024 is $3,834,204,000.On average, 10 Wall Street analysts forecast JAZZ's revenue for 2024 to be $254,128,164,193, with the lowest JAZZ revenue forecast at $249,574,402,377, and the highest JAZZ revenue forecast at $257,183,644,167. On average, 10 Wall Street analysts forecast JAZZ's revenue for 2025 to be $275,118,200,002, with the lowest JAZZ revenue forecast at $258,770,331,620, and the highest JAZZ revenue forecast at $289,236,601,063.
In 2026, JAZZ is forecast to generate $286,684,808,630 in revenue, with the lowest revenue forecast at $258,025,928,941 and the highest revenue forecast at $316,572,513,848.